BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35848083)

  • 1. Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab.
    Takahashi S; Narita S; Fujiyama N; Hatakeyama S; Kobayashi T; Kato R; Naito S; Sakatani T; Kashima S; Koizumi A; Yamamoto R; Nara T; Kanda S; Numakura K; Saito M; Obara W; Tsuchiya N; Ohyama C; Ogawa O; Habuchi T
    Cancer Sci; 2022 Dec; 113(12):4059-4069. PubMed ID: 35848083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
    Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
    Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types.
    Chhibber A; Huang L; Zhang H; Xu J; Cristescu R; Liu X; Mehrotra DV; Shen J; Shaw PM; Hellmann MD; Snyder A
    Immunity; 2022 Jan; 55(1):56-64.e4. PubMed ID: 34986342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
    Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study.
    Minato A; Furubayashi N; Harada M; Negishi T; Sakamoto N; Song Y; Hori Y; Tomoda T; Tamura S; Kuroiwa K; Seki N; Tomisaki I; Harada K; Nakamura M; Fujimoto N
    Clin Genitourin Cancer; 2022 Oct; 20(5):499.e1-499.e8. PubMed ID: 35624001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer.
    Inoue S; Sassa N; Kawanishi H; Yuguchi Y; Suzuki T; Nagayama J; Matsui H; Miyata Y; Soeda Y; Tochigi K; Yamauchi Y; Maeda M; Kobayashi I; Hattori R; Matsukawa Y; Kato M
    Anticancer Res; 2022 Jul; 42(7):3627-3636. PubMed ID: 35790259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.
    Correale P; Saladino RE; Giannarelli D; Giannicola R; Agostino R; Staropoli N; Strangio A; Del Giudice T; Nardone V; Altomonte M; Pastina P; Tini P; Falzea AC; Imbesi N; Arcati V; Romeo G; Caracciolo D; Luce A; Caraglia M; Giordano A; Pirtoli L; Necas A; Amler E; Barbieri V; Tassone P; Tagliaferri P
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy.
    Chowell D; Krishna C; Pierini F; Makarov V; Rizvi NA; Kuo F; Morris LGT; Riaz N; Lenz TL; Chan TA
    Nat Med; 2019 Nov; 25(11):1715-1720. PubMed ID: 31700181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.
    Ogihara K; Kikuchi E; Shigeta K; Okabe T; Hattori S; Yamashita R; Yoshimine S; Shirotake S; Nakazawa R; Matsumoto K; Mizuno R; Hara S; Oyama M; Masuda T; Niwakawa M; Oya M
    Urol Oncol; 2020 Jun; 38(6):602.e1-602.e10. PubMed ID: 32139290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching.
    Nishiyama N; Kobayashi T; Narita S; Hidaka Y; Ito K; Maruyama S; Mukai S; Tsutsumi M; Miki J; Okuno T; Yoshio Y; Matsumoto H; Shimazui T; Segawa T; Karashima T; Masui K; Fukuta F; Tashiro K; Imai K; Suekane S; Nagasawa S; Higashi S; Fukui T; Kojima T; Morita S; Ogawa O; Nishiyama H; Kitamura H;
    J Geriatr Oncol; 2022 Jan; 13(1):88-93. PubMed ID: 34238726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.
    Kobayashi M; Narita S; Matsui Y; Kanda S; Hidaka Y; Abe H; Tsuzuki T; Ito K; Kojima T; Kato M; Hatakeyama S; Matsushita Y; Naito S; Shiga M; Miyake M; Muro Y; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Taoka R; Kamiyama M; Morita S; Habuchi T; Ogawa O; Nishiyama H; Kitamura H; Kobayashi T;
    BJU Int; 2022 Aug; 130(2):226-234. PubMed ID: 34110696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study.
    Dang E; Vallée A; Lepage-Seydoux C; Sejean K; Bonan B; Abraham C; Beuzeboc P; Ratta R
    Curr Oncol; 2022 Feb; 29(2):945-955. PubMed ID: 35200579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.
    Iafolla MAJ; Yang C; Chandran V; Pintilie M; Li Q; Bedard PL; Hansen A; Lheureux S; Spreafico A; Razak AA; Hakgor S; Giesler A; Pugh TJ; Siu LL
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33554038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
    Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
    Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single-center analysis in Japan.
    Fujiwara M; Yuasa T; Urasaki T; Komai Y; Fujiwara R; Numao N; Yamamoto S; Yonese J
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1398. PubMed ID: 33934570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower neutrophil-to-lymphocyte ratio and positive programmed cell death ligand-1 expression are favorable prognostic markers in patients treated with pembrolizumab for urothelial carcinoma.
    Miyama Y; Kaneko G; Nishimoto K; Yasuda M
    Cancer Med; 2022 Nov; 11(22):4236-4245. PubMed ID: 35699000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.